The North America Clot Busting Drugs Market would witness market growth of 6.6% CAGR during the forecast period (2023-2030).
Thrombolytic drugs, commonly called clot-busting pharmaceuticals, are prescribed to treat particular medical conditions by dissolving blood clots. These drugs offer many benefits in the treatment of specific disorders. Blood clots can be promptly removed with the help of clot-busting drugs, especially when they are present suddenly, like ischemic strokes or myocardial infarctions (heart attacks). They work by triggering the body's clot-dissolving mechanism, aiding in blood flow recovery to the injured organ.
In rare cases, clot-busting drugs may be utilized instead of surgery. For instance, thrombolytic therapy can help dissolve the clot and clear the obstruction in pulmonary embolism when a blood clot stops the blood vessels in the lungs. This might eliminate the need for more invasive procedures like surgical embolectomy. The market is expected to increase more rapidly in the coming years due to all these factors.
Careful and controlled dosing is necessary to prevent excessive bleeding from wounds or cuts, allergic responses brought on by clot busters, low blood pressure, unusual bleeding in the urine or stools, and other drug side effects. Rarely are alternatives to clot-busting drugs available for the treatment of blood clots. Anticoagulant medications (like heparin or direct oral anticoagulants) may be the primary treatment in some cases of deep vein thrombosis or pulmonary embolism.
Heart disease is the primary cause of death in the United States, and stroke is the fifth leading cause. Cardiovascular health is improved as part of the Healthy People 2030 initiative, which focuses on preventing and treating heart disease and stroke. The second greatest cause of death in Canada is heart disease. According to data from the Canadian Chronic Disease Surveillance System (CCDSS) for 2017-2018, approximately 1 in 12 (or 2.6 million) Canadian individuals aged 20 and over encountered heart disease, and every hour, 14 Canadian adults age 20 and over with heart disease die. As a result of this high prevalence of such conditions, the market is estimated to grow.
The US market dominated the North America Clot Busting Drugs Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $11.7 billion by 2030. The Canada market is estimated to witness a CAGR of 9% during (2023 - 2030). Additionally, The Mexico market would showcase a CAGR of 8.1% during (2023 - 2030).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product, the market is segmented into Anticoagulants, Thrombolytic Drugs, Anti-Platelet Drugs and Others. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Indication, the market is segmented into Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Clot Busting Drugs Market is Projected to reach USD 47.7 Billion by 2030, at a CAGR of 7.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Dr. Reddy’s Laboratories Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Eli Lilly And Company, Johnson & Johnson (Johnson & Johnson Services, Inc.), Pfizer, Inc., Merck & Co., Inc.
By Distribution Channel
By Product
By Route of Administration
By Indication
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 